B Cell Tolerance and Targeted Therapies in SLE

Overview

Journal J Clin Med

Specialty General Medicine

Date 2023 Oct 14

PMID 37834911

Authors

Ioannis Parodis

Xuan Long

Mikael C I Karlsson

Xin Huang

Affiliations

Soon will be listed here.

Abstract

Systemic Lupus Erythematosus (SLE) is a chronic systemic autoimmune disease of high clinical and molecular heterogeneity, and a relapsing-remitting pattern. The disease is currently without cure and more prevalent in women. B cell tolerance and production of autoantibodies are critical mechanisms that drive SLE pathophysiology. However, how the balance of the immune system is broken and how the innate and adaptive immune systems are interacting during lupus-specific autoimmune responses are still largely unknown. Here, we review the latest knowledge on B cell development, maturation, and central versus peripheral tolerance in connection to SLE and treatment options. We also discuss the regulation of B cells by conventional T cells, granulocytes, and unconventional T cells, and how effector B cells exert their functions in SLE. We also discuss mechanisms of action of B cell-targeted therapies, as well as possible future directions based on current knowledge of B cell biology.

Citing Articles

Mechanistic Evaluation of Anti-CD19 CAR-T Cell Therapy Repurposed in Systemic Lupus Erythematosus Using a Quantitative Systems Pharmacology Model.

Park H, Mugundu G, Singh A Clin Transl Sci. 2025; 18(2):e70146.

PMID: 39936636 PMC: 11815715. DOI: 10.1111/cts.70146.

Major Systemic Lupus Erythematosus Exacerbation after Severe Clostridium Difficile Infection: A Case Report.

Partalidou S, Katsigianni I, Tara V, Retzeperi E, Radounislis A, Neofytou I Mediterr J Rheumatol. 2025; 35(4):684-687.

PMID: 39886284 PMC: 11778607. DOI: 10.31138/mjr.190224.msl.

Induction of interleukin 21 receptor expression via enhanced intracellular metabolism in B cells and its relevance to the disease activity in systemic lupus erythematosus.

Ueno M, Iwata S, Yamagata K, Todoroki Y, Sonomoto K, Nagayasu A RMD Open. 2024; 10(4.

PMID: 39740932 PMC: 11749818. DOI: 10.1136/rmdopen-2024-004567.

Progress of rituximab in the treatment of systemic lupus erythematosus and lupus nephritis.

Mo S, Li Y, He J, Lin L Front Med (Lausanne). 2024; 11:1472019.

PMID: 39430591 PMC: 11486751. DOI: 10.3389/fmed.2024.1472019.

Molecular profiling and therapeutic tailoring to address disease heterogeneity in systemic lupus erythematosus.

Karmakar A, Kumar U, Prabhu S, Ravindran V, Nagaraju S, Suryakanth V Clin Exp Med. 2024; 24(1):223.

PMID: 39294397 PMC: 11410857. DOI: 10.1007/s10238-024-01484-z.

References

Shen P, Fillatreau S . Antibody-independent functions of B cells: a focus on cytokines. Nat Rev Immunol. 2015; 15(7):441-51. DOI: 10.1038/nri3857. View

Plesner T, Krejcik J . Daratumumab for the Treatment of Multiple Myeloma. Front Immunol. 2018; 9:1228. PMC: 5994592. DOI: 10.3389/fimmu.2018.01228. View

Nikolopoulos D, Parodis I . Janus kinase inhibitors in systemic lupus erythematosus: implications for tyrosine kinase 2 inhibition. Front Med (Lausanne). 2023; 10:1217147. PMC: 10344364. DOI: 10.3389/fmed.2023.1217147. View

Mysler E, Spindler A, Guzman R, Bijl M, Jayne D, Furie R . Efficacy and safety of ocrelizumab in active proliferative lupus nephritis: results from a randomized, double-blind, phase III study. Arthritis Rheum. 2013; 65(9):2368-79. DOI: 10.1002/art.38037. View

Garimella M, He C, Chen G, Li Q, Huang X, Karlsson M . The B cell response to both protein and nucleic acid antigens displayed on apoptotic cells are dependent on endosomal pattern recognition receptors. J Autoimmun. 2020; 117:102582. DOI: 10.1016/j.jaut.2020.102582. View

Stohl W, Hiepe F, Latinis K, Thomas M, Scheinberg M, Clarke A . Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus. Arthritis Rheum. 2012; 64(7):2328-37. PMC: 3350827. DOI: 10.1002/art.34400. View

Furie R, Stohl W, Ginzler E, Becker M, Mishra N, Chatham W . Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus. Arthritis Res Ther. 2008; 10(5):R109. PMC: 2592791. DOI: 10.1186/ar2506. View

Bedard M, Shrestha D, Priestman D, Wang Y, Schneider F, Matute J . Sterile activation of invariant natural killer T cells by ER-stressed antigen-presenting cells. Proc Natl Acad Sci U S A. 2019; 116(47):23671-23681. PMC: 6876220. DOI: 10.1073/pnas.1910097116. View

Merrill J, Wallace D, Wax S, Kao A, Fraser P, Chang P . Efficacy and Safety of Atacicept in Patients With Systemic Lupus Erythematosus: Results of a Twenty-Four-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm, Phase IIb Study. Arthritis Rheumatol. 2017; 70(2):266-276. PMC: 6099253. DOI: 10.1002/art.40360. View

10.

Petkau G, Turner M . Signalling circuits that direct early B-cell development. Biochem J. 2019; 476(5):769-778. DOI: 10.1042/BCJ20180565. View

11.

Meffre E, OConnor K . Impaired B-cell tolerance checkpoints promote the development of autoimmune diseases and pathogenic autoantibodies. Immunol Rev. 2019; 292(1):90-101. PMC: 9145185. DOI: 10.1111/imr.12821. View

12.

Walhelm T, Gunnarsson I, Heijke R, Leonard D, Trysberg E, Eriksson P . Clinical Experience of Proteasome Inhibitor Bortezomib Regarding Efficacy and Safety in Severe Systemic Lupus Erythematosus: A Nationwide Study. Front Immunol. 2021; 12:756941. PMC: 8517506. DOI: 10.3389/fimmu.2021.756941. View

13.

Mockel T, Basta F, Weinmann-Menke J, Schwarting A . B cell activating factor (BAFF): Structure, functions, autoimmunity and clinical implications in Systemic Lupus Erythematosus (SLE). Autoimmun Rev. 2020; 20(2):102736. DOI: 10.1016/j.autrev.2020.102736. View

14.

Alexander T, Sarfert R, Klotsche J, Kuhl A, Rubbert-Roth A, Lorenz H . The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus. Ann Rheum Dis. 2015; 74(7):1474-8. PMC: 4484251. DOI: 10.1136/annrheumdis-2014-206016. View

15.

Walsh K, Mills K . Dendritic cells and other innate determinants of T helper cell polarisation. Trends Immunol. 2013; 34(11):521-30. DOI: 10.1016/j.it.2013.07.006. View

16.

Menon M, Blair P, Isenberg D, Mauri C . A Regulatory Feedback between Plasmacytoid Dendritic Cells and Regulatory B Cells Is Aberrant in Systemic Lupus Erythematosus. Immunity. 2016; 44(3):683-697. PMC: 4803914. DOI: 10.1016/j.immuni.2016.02.012. View

17.

Azevedo Portilho N, Scarfo R, Bertesago E, Ismailoglu I, Kyba M, Kobayashi M . B1 lymphocytes develop independently of Notch signaling during mouse embryonic development. Development. 2021; 148(15). PMC: 8380455. DOI: 10.1242/dev.199373. View

18.

Fan J, Luo J, Yan C, Hao R, Zhao X, Jia R . Methotrexate, combined with cyclophosphamide attenuates murine collagen induced arthritis by modulating the expression level of Breg and DCs. Mol Immunol. 2017; 90:106-117. DOI: 10.1016/j.molimm.2017.07.001. View

19.

Tam C, Trotman J, Opat S, Burger J, Cull G, Gottlieb D . Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL. Blood. 2019; 134(11):851-859. PMC: 6742923. DOI: 10.1182/blood.2019001160. View

20.

Isenberg D, Furie R, Jones N, Guibord P, Galanter J, Lee C . Efficacy, Safety, and Pharmacodynamic Effects of the Bruton's Tyrosine Kinase Inhibitor Fenebrutinib (GDC-0853) in Systemic Lupus Erythematosus: Results of a Phase II, Randomized, Double-Blind, Placebo-Controlled Trial. Arthritis Rheumatol. 2021; 73(10):1835-1846. DOI: 10.1002/art.41811. View